Roche to Initiate P-III COVACTA Study of Actemra/RoActemra in Hospitalized Patients with Severe Covid-19 Pneumonia in Collaboration with BARDA

 Roche to Initiate P-III COVACTA Study of Actemra/RoActemra in Hospitalized Patients with Severe Covid-19 Pneumonia in Collaboration with BARDA

Roche to Initiate P-III COVACTA Study of Actemra/RoActemra in Hospitalized Patients with Severe Covid-19 Pneumonia in Collaboration with BARDA

Shots:

  • The P-III COVACTA study will evaluate the safety and efficacy of Actemra/RoActemra (tocilizumab) + SOC vs PBO + SOC in adult hospitalized patients with severe COVID-19 pneumonia
  • The study is expected to be initiated in early Apr’2020 and will evaluate the therapy in ~300 patients globally, including the US with the 1EPs & 2EPs as clinical status, mortality, mechanical ventilation and ICU variables
  • Actemra/RoActemra (IV, SC) is the first approved anti-IL-6 receptor biologic indicated to treat patients with moderate-to-severe active RA. Additionally, Roche received FDA’s EUA for the cobas SARS-CoV-2 Test on Mar 13, 2020, to detect COVID-19

Click here ­to­ read full press release/ article | Ref: Roche | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post